DNA icon

Very Long Chain Acyl-CoA Dehydrogenase Deficiency via the ACADVL Gene

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
ACADVL 81406 81406,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
9507ACADVL81406 81406,81479 $990 Order Options and Pricing

Pricing Comments

Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information. If the Sanger option is selected, CNV detection may be ordered through Test #600.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).

The Sanger Sequencing method for this test is NY State approved.

For Sanger Sequencing click here.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Maxime Cadieux-Dion, PhD

Clinical Features and Genetics

Clinical Features

Very long chain acyl-CoA dehydrogenase deficiency (VLCADD, OMIM #201475) is a defect in the breakdown of very long chain (C14-C20) fatty acids within the mitochondria. The severity of VLCADD varies over a wide range and can be divided into three clinical groups:

(1) severe, early-onset, cardiac and multiorgan failure - within the first few months of life, affected individuals present with cardiomyopathy, arrhythmias, pericardial effusion, hepatomegaly, hypotonia, and episodes of hypoketotic hypoglycemia;

(2) hepatic or hypoketotic hypoglycemia - individuals present in early childhood with hepatomegaly and hypoketotic hypoglycemia but without the cardiac issues;

(3) later-onset episodic myopathic form - individuals are diagnosed in adolescence or adult life with muscle weakness and pain, which can be induced by exercise.

VLCADD may be detected through tandem mass spectrometry in routine neonatal screening, though affected individuals with milder phenotypes may not be identified during times of physiologic health. Incidence of VLCADD in the United States is estimated to be 1/30,000.


Very long chain acyl-CoA dehydrogenase (VLCAD), encoded by the ACADVL gene, catalyzes the first step in the catabolism of fatty acids with 14-20 carbon atoms. VLCAD deficiency exhibits autosomal recessive inheritance. Hundreds of causative ACADVL variants have been reported to date. Variants are located throughout the gene and are roughly 60% missense and 40% frameshift, splicing, or nonsense. One variant, p.Val283Ala, accounts for 20% of the pathologic alleles among those identified by newborn screening. Variants which completely eliminate enzyme activity usually cause the most severe disease, while missense variants resulting in some residual enzyme activity lead to milder childhood and adult onset forms (Andresen et al. Am J Hum Genet 64:479-494, 1999; Gregersen et al. Hum Mutat 18:169-189, 2001).

Clinical Sensitivity - Sequencing with CNV PGxome

Andresen et al. (Am J Hum Genet 64:479-494, 1999) performed ACADVL gene sequencing on 55 VLCADD patients with demonstrated enzyme deficiency and found two likely causative variants in 47 patients (85%) and one likely causative variant in the remaining 8 patients. Boneh et al. (Mol Genet Metab 88:166-170, 2006) found two causative variants in 6 of 6 patients identified through neonatal screening. Analytical sensitivity should be high because nearly all variants reported to date are expected to be detected by sequence analysis of genomic DNA.

Testing Strategy

This test provides full coverage of all coding exons of the ACADVL gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Infants identified by newborn screening with VLCADD. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in ACADVL.


Official Gene Symbol OMIM ID
ACADVL 609575
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Very Long Chain Acyl-CoA Dehydrogenase Deficiency AR 201475


  • Andresen, B. S., et.al. (1999). "Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency." Am J Hum Genet 64(2): 479-94. PubMed ID: 9973285
  • Boneh, A., et.al. (2006). "VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis." Mol Genet Metab 88(2): 166-70. PubMed ID: 16488171
  • Gregersen, N., et.al. (2001). "Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship." Hum Mutat 18(3): 169-89. PubMed ID: 11524729


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard